ReviewAnnual review of pharmacology and toxicology2019
Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries.
Review in Annual review of pharmacology and toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- ILAE-YES global webinar series: Integrating clinical and basic science in epilepsy research.Epilepsia open · 2026Article
- Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.Journal of virology · 2026Review
- Smart biomaterials for skeletal aging repair and regeneration.Bone research · 2026Review
- Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders.Drug delivery and translational research · 2025Article
- Dynamic clinical trial success rates for drugs in the 21st century.Nature communications · 2025Article
- The potential of academic drug discovery: successes and challenges.Expert opinion on drug discovery · 2025Article
- Selective serotonin reuptake inhibitors and osteoporosis: a target trial emulation using real-world data.Acta neuropsychiatrica · 2025Article
- Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.ACS pharmacology & translational science · 2025Review
- Challenges and opportunities of translating animal research into human trials in Ethiopia.BMC medical research methodology · 2024Article
- SPARKing academic technologies across the valley of death.Nature biotechnology · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Unmet medical needs definition and incentives: stakeholders perspectives on the reform of the EU pharmaceutical legislation.Frontiers in medicine · 2024Article
- Review
- Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe.Clinical pharmacology and therapeutics · 2023Article
- Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries.Frontiers in reproductive health · 2023Review
- Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022Review
- The Health Care Sector's Experience of Blockchain: A Cross-disciplinary Investigation of Its Real Transformative Potential.Journal of medical Internet research · 2021Article
- A "Failed" Assay Development for the Discovery of Rescuing Small Molecules from the Radiation Damage.SLAS discovery : advancing life sciences R & D · 2021Article
- On the road to smart biomaterials for bone research: definitions, concepts, advances, and outlook.Bone research · 2021Review
- Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.SLAS discovery : advancing life sciences R & D · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
With pharmaceutical companies shrinking their research departments and exiting out of efforts related to unprofitable diseases, society has become increasingly dependent on academic institutions to perform drug discovery and early-stage translational research. Academic drug discovery and translational research programs assist in shepherding promising therapeutic opportunities through the so-called valley of death in the hope that a successful new drug will result in saved lives, improved health, economic growth, and financial return. We have interviewed directors of 16 such academic programs in the United States and found that these programs and the projects therein face numerous challenges in reaching the clinic, including limited funding, lack of know-how, and lack of a regional drug development ecosystem. If these issues can be addressed through novel industry partnerships, the revision of government policies, and expanded programs in translational education, more effective new therapies are more likely to reach patients in need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.